Research programme: phosphodiesterase inhibitors - Acorda Therapeutics

Drug Profile

Research programme: phosphodiesterase inhibitors - Acorda Therapeutics

Alternative Names: BTT 5001; ELB 526; ELB-WE-007; WE-1

Latest Information Update: 02 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator elbion NV
  • Developer Biotie Therapies Corp.
  • Class 3-ring heterocyclic compounds; Imidazoles; Pyrazines; Pyrimidines; Quinoxalines; Small molecules; Triazines
  • Mechanism of Action Phosphodiesterase 10A inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders; Inflammation; Schizophrenia

Most Recent Events

  • 04 Nov 2010 Biotie decides to exclusively focus on clinical development and announces a restructuring plan to spin-off its preclinical CNS pipeline and phosphodiesterase enzyme (PDE) inhibitor platform to BioCrea
  • 04 Nov 2010 Discontinued - Preclinical for CNS disorders in Germany (PO)
  • 04 Nov 2010 Discontinued - Preclinical for Schizophrenia in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top